H2N2V1, Main, Exploration, bibRecord, 001C90

Use of antivirals in influenza in the elderly : Prophylaxis and therapy

Identifieur interne : 001C90 ( Main/Exploration ); précédent : 001C89; suivant : 001C91

Use of antivirals in influenza in the elderly : Prophylaxis and therapy

Auteurs : K. G. Nicholson [Royaume-Uni]

Source :

Gerontology : (Basel) [ 0304-324X ] ; 1996.

RBID : Pascal:96-0478391

Descripteurs français

KwdFr :
- Amantadine (usage thérapeutique), Antiviraux (usage thérapeutique), Facteurs de risque, Flambées de maladies, Grippe humaine (), Grippe humaine (épidémiologie), Humains, Orthomyxoviridae (physiologie), Rimantadine (usage thérapeutique), Réplication virale (), Résultat thérapeutique, Sujet âgé.
MESH :
- physiologie : Orthomyxoviridae.
- usage thérapeutique : Amantadine, Antiviraux, Rimantadine.
- épidémiologie : Grippe humaine.
Pascal (Inist)
- Facteurs de risque, Flambées de maladies, Grippe humaine, Humains, Influenzavirus A, Chimiothérapie, Réplication virale, Résultat thérapeutique, Sujet âgé, Traitement, Prévention, Toxicité, Pharmacocinétique, Article synthèse, Grippe, Rimantadine, Amantadine, Antiviral, Vieillard.

English descriptors

KwdEn :
- Aged, Amantadine (therapeutic use), Antiviral, Antiviral Agents (therapeutic use), Chemotherapy, Disease Outbreaks, Elderly, Humans, Influenza, Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenzavirus A, Orthomyxoviridae (physiology), Pharmacokinetics, Prevention, Review, Rimantadine (therapeutic use), Risk Factors, Toxicity, Treatment, Treatment Outcome, Virus Replication (drug effects).
MESH :
- chemical , therapeutic use : Amantadine, Antiviral Agents, Rimantadine.
- drug effects : Virus Replication.
- epidemiology : Influenza, Human.
- physiology : Orthomyxoviridae.
- prevention & control : Influenza, Human.
- Aged, Disease Outbreaks, Humans, Risk Factors, Treatment Outcome.

Abstract

Amantadine and rimantadine inhibit H1N1, H2N2, and H3N2 strains of influenza A, but not influenza B. Rimantadine exerts somewhat greater antiviral activity than amantadine, and there are several potentially important differences between the pharmacokinetic profiles and elimination pathways of the two drugs in favour of rimantadine. Adverse effects are more prominent in the elderly but can be minimized by dosage reductions. Both drugs are effective prophylactically and therapeutically and can be used for 'seasonal' prophylaxis, postexposure prophylaxis, outbreak control in residential care, and treatment during community outbreaks of influenza A. Drug-resistant strains of influenza have been recovered in up to half the subjects undergoing treatment, and prophylaxis may fail in homes where drug is given for both prophylaxis and therapy. Elderly residential patients and others identified by national immunization policies may benefit most from prophylactic administration of drug when influenza is first identified locally and for the duration of the outbreak.

Affiliations:

Royaume-Uni

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Use of antivirals in influenza in the elderly : Prophylaxis and therapy</title>
<author><name sortKey="Nicholson, K G" sort="Nicholson, K G" uniqKey="Nicholson K" first="K. G." last="Nicholson">K. G. Nicholson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Infectious Diseases and Tropical Disease, Leicester Royal Infirmary</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Leicester</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0478391</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0478391 INIST</idno>
<idno type="RBID">Pascal:96-0478391</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000086</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000128</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000086</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000086</idno>
<idno type="wicri:doubleKey">0304-324X:1996:Nicholson K:use:of:antivirals</idno>
<idno type="wicri:Area/Main/Merge">001D58</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8940651</idno>
<idno type="wicri:Area/PubMed/Corpus">000403</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000403</idno>
<idno type="wicri:Area/PubMed/Curation">000403</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000403</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000358</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000358</idno>
<idno type="wicri:Area/Ncbi/Merge">001339</idno>
<idno type="wicri:Area/Ncbi/Curation">001339</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001339</idno>
<idno type="wicri:doubleKey">0304-324X:1996:Nicholson K:use:of:antivirals</idno>
<idno type="wicri:Area/Main/Merge">001C63</idno>
<idno type="wicri:Area/Main/Curation">001C90</idno>
<idno type="wicri:Area/Main/Exploration">001C90</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Use of antivirals in influenza in the elderly : Prophylaxis and therapy</title>
<author><name sortKey="Nicholson, K G" sort="Nicholson, K G" uniqKey="Nicholson K" first="K. G." last="Nicholson">K. G. Nicholson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Infectious Diseases and Tropical Disease, Leicester Royal Infirmary</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Leicester</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Gerontology : (Basel)</title>
<title level="j" type="abbreviated">Gerontology : (Basel)</title>
<idno type="ISSN">0304-324X</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Gerontology : (Basel)</title>
<title level="j" type="abbreviated">Gerontology : (Basel)</title>
<idno type="ISSN">0304-324X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Amantadine (therapeutic use)</term>
<term>Antiviral</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Disease Outbreaks</term>
<term>Elderly</term>
<term>Humans</term>
<term>Influenza</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenzavirus A</term>
<term>Orthomyxoviridae (physiology)</term>
<term>Pharmacokinetics</term>
<term>Prevention</term>
<term>Review</term>
<term>Rimantadine (therapeutic use)</term>
<term>Risk Factors</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amantadine (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Facteurs de risque</term>
<term>Flambées de maladies</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Orthomyxoviridae (physiologie)</term>
<term>Rimantadine (usage thérapeutique)</term>
<term>Réplication virale ()</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Antiviral Agents</term>
<term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amantadine</term>
<term>Antiviraux</term>
<term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Disease Outbreaks</term>
<term>Humans</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Facteurs de risque</term>
<term>Flambées de maladies</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Influenzavirus A</term>
<term>Chimiothérapie</term>
<term>Réplication virale</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Traitement</term>
<term>Prévention</term>
<term>Toxicité</term>
<term>Pharmacocinétique</term>
<term>Article synthèse</term>
<term>Grippe</term>
<term>Rimantadine</term>
<term>Amantadine</term>
<term>Antiviral</term>
<term>Vieillard</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Amantadine and rimantadine inhibit H1N1, H2N2, and H3N2 strains of influenza A, but not influenza B. Rimantadine exerts somewhat greater antiviral activity than amantadine, and there are several potentially important differences between the pharmacokinetic profiles and elimination pathways of the two drugs in favour of rimantadine. Adverse effects are more prominent in the elderly but can be minimized by dosage reductions. Both drugs are effective prophylactically and therapeutically and can be used for 'seasonal' prophylaxis, postexposure prophylaxis, outbreak control in residential care, and treatment during community outbreaks of influenza A. Drug-resistant strains of influenza have been recovered in up to half the subjects undergoing treatment, and prophylaxis may fail in homes where drug is given for both prophylaxis and therapy. Elderly residential patients and others identified by national immunization policies may benefit most from prophylactic administration of drug when influenza is first identified locally and for the duration of the outbreak.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Nicholson, K G" sort="Nicholson, K G" uniqKey="Nicholson K" first="K. G." last="Nicholson">K. G. Nicholson</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C90 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C90 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:96-0478391
   |texte=   Use of antivirals in influenza in the elderly : Prophylaxis and therapy
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

Serveur d'exploration H2N2

Use of antivirals in influenza in the elderly : Prophylaxis and therapy

Use of antivirals in influenza in the elderly : Prophylaxis and therapy

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.